IDiyas

For the Inventor, By the Inventor

Berlin, Germany

Martin Schneider

USPTO Granted Patents = 27

Average Co-Inventor Count = 4.7

ph-index = 8

Forward Citations = 223(Granted Patents)


Company Filing History:

goldMedal26 out of 1,384 
 
Schering Aktiengesellschaft
 patents
silverMedal1 out of 7 
 
Shering Ag
 patents

Years Active: 1992-2008

Loading Chart...
27 patents (USPTO):Explore Patents
1. 7378406 - Use of antiprogestins for prophylaxis and treatment of hormone-dependent diseases (2008-05-27),
2. 7148213 - Antigestagenically active steroids with a fluorinated 17α-alkyl chain (2006-12-12),
3. 6806263 - Antigestagenically active steroids with a fluorinated 17-alpha-alkyl chain (2004-10-19),
4. 6780855 - 11&bgr;-HALOGEN-7&agr;-SUBSTITUTED ESTRATRIENES, PROCESS FOR THE PRODUCTION OF PHARMACEUTICAL PREPARATIONS THAT CONTAIN THESE 11&bgr;-HALOGEN-7&agr;-SUBSTITUTED ESTRATRIENES AS WELL AS THEIR USE FOR THE PRODUCTION OF PHARMACEUTICAL AGENTS (2004-08-24),
5. 6767903 - New7&agr;, 17&agr;-bis-alkylated testosterone derivatives and their use in long-term therapy of androgen-dependent diseases (2004-07-27),
6. 6503938 - 2-phenylindoles as antiestrogenic pharmaceutical agents (2003-01-07),
7. 6503895 - Antigestagenically active steroids with a fluorinated 17&agr;-alkyl chain (2003-01-07),
8. 6316432 - Antigestagenically active steroids with a flourinated 17 &agr;-alkyl chain (2001-11-13),
9. 6288051 - 7 &agr;-(5-methylaminopentyl)-estratrienes, process for their production, pharmaceutical preparations that contain these 7 &agr;(5-methylaminopentyl)-estratrienes as well as their use for the production of pharmaceutical agents (2001-09-11),
10. 6271403 - 7&agr;-(xi-aminoalkyl)-estratrienes, process for their production, pharmaceutical preparations which contain these 7&agr;-(xi-aminoalkyl-estratrienes as well as their use for the production of pharmaceutical agents (2001-08-07),
11. 6147105 - 2-phenylindoles as antiestrogenic pharmaceutical agents (2000-11-14),
12. 6096732 - Steroid esters, process for their production and their pharmaceutical use (2000-08-01),
13. 5986115 - 7.alpha.-(.xi.-aminoalkyl)-estratrienes, process for their production, (1999-11-16),
14. 5866560 - 7.alpha.-(.xi.-aminoalkyl)-estratrienes, process for their production, (1999-02-02),
15. 5843931 - 6,7-modified 11.beta.-aryl-4-oestrenes (1998-12-01),

Title: Martin Schneider: Pioneering Advances in Hormone-Dependent Disease Treatments

Introduction

Martin Schneider is an accomplished inventor based in Berlin, Germany, known for his significant contributions to the field of pharmaceuticals. With an impressive portfolio of 27 patents, Schneider has focused on innovative methods for preventing and treating hormone-dependent diseases, particularly breast cancer. His research has paved the way for novel therapeutic approaches that are critical in modern medicine.

Latest Patents

Among Schneider's recent breakthroughs is a patent concerning the "Use of antiprogestins for prophylaxis and treatment of hormone-dependent diseases." This invention outlines methods for preventing or treating hormone-dependent conditions using antiprogestins, specifically highlighting antiprogestin 11β-(4-acetylphenyl)-17β-hydroxy-17α-(1,1,2,2,2-pentafluoroethyl)-estra-4,9-dien-3-one and its pharmaceutically acceptable derivatives. The invention further includes pharmaceutical compositions that utilize these antiprogestins, offering new hope in combatting diseases like breast cancer.

Another noteworthy patent involves "Antigestagenically active steroids with a fluorinated 17α-alkyl chain." This innovation describes new 17α-fluoroalkyl steroids and their physiologically compatible salts, highlighting their strong antigestagenic properties and potential applications in pharmaceutical preparations.

Career Highlights

Throughout his career, Martin Schneider has made significant contributions while working for prominent companies in the pharmaceutical sector. He gained valuable experience during his tenure at Schering Aktiengesellschaft and Shering AG. These roles have enabled him to collaborate on cutting-edge research that impacts treatment strategies for hormone-dependent conditions.

Collaborations

Schneider's innovative journey has been enriched through collaboration with esteemed colleagues, including Rolf Bohlmann and Yukishige Nishino. These partnerships have bolstered his research efforts and have significantly contributed to the advancement of pharmaceutical science aimed at addressing critical health challenges.

Conclusion

Martin Schneider stands out as a pivotal figure in the realm of pharmaceutical innovation, driving forward the development of therapeutic solutions for hormone-dependent diseases. His patents reflect a commitment to improving healthcare outcomes and advancing scientific knowledge. Through continuous research and collaboration, Schneider is poised to contribute even more to the field, ensuring that his inventions remain at the forefront of medical advancements.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…